» Articles » PMID: 35830357

Prognostic Factors of Elderly Patients with Hepatocellular Carcinoma: Should We Be More Courageous in Treatment?

Overview
Specialty Gastroenterology
Date 2022 Jul 13
PMID 35830357
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: Hepatocellular carcinoma (HCC) is a cancer with a poor prognosis, its incidence increases with age. The risk of developing HCC is highest in the seventh decade. In this study, we aimed to determine the clinicopathological differences, treatment choices, survival times, and effective prognostic factors of HCC in the elderly and young populations.

Methods: All patients aged ≥18 years who were diagnosed histologically between 2016 and 2020 were included in the study. Patients were divided into two groups: <70 years and ≥70 years. The clinicopathological differences, treatment choices, survival times, and effective prognostic factors of HCC were compared in the elderly and young populations.

Results: A total of 407 patients were evaluated. There were 164 patients (40.3%) in the geriatric age group. There was no significant difference in the female/male ratio, the laboratory values, survival time between the two groups. There was no significant difference between the two groups in terms of tumor focality and portal vein invasion ( P > 0.05). The presence of NAFLD, maximal tumor diameter (MTD), and portal invasion were found to be significant for survival according to the univariate analysis in elderly group ( P < 0.05). In the multivariate analysis, presence of NAFLD etiologically, and MTD independent risk factors were observed in elderly group ( P < 0.05).

Conclusion: If the clinicomorphological features of the tumor and prognostic risk factors can be determined by examining the patients in detail, all treatments can be easily applied in the geriatric group.

Citing Articles

Efficacy and Safety of Transarterial Radioembolization in Elderly Patients with Hepatocellular Carcinoma: A Single-Center Experience.

Karaogullarindan U, Gumurdulu Y, Uskudar O, Odabas E, Guler H, Geckalan C Turk J Gastroenterol. 2024; 35(3):204-211.

PMID: 39128104 PMC: 11059000. DOI: 10.5152/tjg.2024.23155.


Thymidine kinase 1 appears to be a marker for the prognosis of hepatocellular carcinoma based on a large-scale, multicenter study.

Jiang Y, Guo L, Han L, Li H, Li C, Wen L J Cancer Res Clin Oncol. 2023; 149(15):14271-14282.

PMID: 37561208 DOI: 10.1007/s00432-023-05089-z.